Biopharmx Corp (BPMX) Sees Large Increase in Short Interest
Biopharmx Corp (NYSE:BPMX) saw a large growth in short interest in the month of October. As of October 13th, there was short interest totalling 4,271,767 shares, a growth of 3.0% from the September 29th total of 4,147,107 shares. Approximately 7.4% of the shares of the company are sold short. Based on an average trading volume of 866,539 shares, the short-interest ratio is currently 4.9 days.
Biopharmx Corp (NYSE BPMX) traded down 5.3241% during mid-day trading on Tuesday, hitting $0.2045. 1,754,495 shares of the stock traded hands. The firm’s market cap is $16.29 million. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $0.90. The stock has a 50-day moving average of $0.30 and a 200 day moving average of $0.44.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/24/biopharmx-corp-bpmx-sees-large-increase-in-short-interest.html.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.